4-(Oxolan-3-yl)piperidine | 1211528-53-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(Oxolan-3-yl)piperidine
• CAS: 1211528-53-8
• 化学式: C₉H₁₇NO
• mdl: MFCD11040367
• 分子量: 155.24
• InChiKey: OHRJLFFWUSVBAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
  申请人：Boehringer Ingelheim Pharma GmbH & CO. KG

  公开号：US20030225079A1

  公开（公告）日：2003-12-04

  The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.

  本发明涉及使用特定的EGF受体拮抗剂制备用于预防和/或治疗良性前列腺增生和/或前列腺肥大的药物组合物，一种治疗或预防良性前列腺增生/前列腺肥大的方法，包括在此处描述的(A)、(B)或(C)组的EGF受体拮抗剂的给药，可选择与已知的治疗良性前列腺增生/前列腺肥大的化合物联合使用，以及相关的药物组合物。
• Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
  申请人：——

  公开号：US20020169180A1

  公开（公告）日：2002-11-14

  The present invention relates to bicyclic heterocycles of general formula 1 wherein R a to R c , A to E and X are defined as in claim 1, the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.

  本发明涉及一般式1的双环杂环化合物，其中R为a到Rc，A到E和X如权利要求1所定义，其互变异构体、立体异构体和盐，特别是其与无机或有机酸或碱的生理可接受盐，具有有价值的药理学特性，特别是对由酪氨酸激酶介导的信号转导具有抑制作用，其在治疗疾病，特别是肿瘤性疾病和肺部和呼吸道疾病中的应用，以及其制备方法。
• Bicyclic Heterocycles, Pharmaceutical Compositions Containing These Compounds, Their Use and Processes for Preparing Them
  申请人：Himmelsbach Frank

  公开号：US20070185091A1

  公开（公告）日：2007-08-09

  The present invention relates to bicyclic heterocycles of general formula wherein R a to R c , A to E and X are defined as in claim 1 , the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.

  本发明涉及通式为的双环杂环化合物 其中Rato Rc，A到E和X的定义如权利要求书中所述，它们的互变异构体、立体异构体和与无机或有机酸或碱形成的生理上可接受的盐，具有有价值的药理学性质，特别是对酪氨酸激酶介导的信号传导具有抑制作用。本发明还涉及这些化合物在治疗疾病，特别是肿瘤性疾病和肺部和呼吸道疾病中的应用，以及它们的制备方法。
• BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM
  申请人：HIMMELSBACH Frank

  公开号：US20100069414A1

  公开（公告）日：2010-03-18

  The present invention relates to bicyclic heterocycles of general formula wherein R a to R c , A to E and X are defined as in claim 1 , the tautomers, stereoisomers and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.

  本发明涉及一般式为的双环杂环化合物，其中Rato Rc，A至E和X如权利要求1所定义，其互变异构体、立体异构体和盐，特别是与无机或有机酸或碱的生理学上可接受的盐，具有有价值的药理学特性，特别是对酪氨酸激酶介导的信号转导具有抑制作用，其在治疗疾病，特别是肿瘤性疾病和肺部和呼吸道疾病方面的用途，以及其制备方法。
• Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
  申请人：Singer Thomas

  公开号：US20070099918A1

  公开（公告）日：2007-05-03

  The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.